Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alvotech ( (ALVO) ) has provided an update.
On December 31, 2025, Alvotech announced it had secured a new USD 100 million senior term loan facility maturing in December 2027, replacing its previous working capital asset-based lending facility and providing full access to the funds throughout the term. Led by GoldenTree Asset Management and bearing a 12.5% cash interest rate with monthly payments, the financing is intended to reinforce liquidity and operational flexibility as Alvotech advances a 30-product biosimilar R&D pipeline, expands production capacity and funds four planned global product launches through 2026, complementing earlier refinancing steps and a recent USD 108 million senior unsecured convertible bond issue that collectively bolster the company’s capital structure and support its strategic growth plans.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotechnology company focused exclusively on developing and manufacturing biosimilar medicines, aiming to provide high-quality, cost-effective alternatives to branded biologics for patients worldwide. The company has five biosimilars already approved and marketed in multiple regions, including versions of Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, and a pipeline of additional candidates targeting autoimmune, eye and bone disorders, respiratory disease and cancer, supported by a broad network of commercial partnerships across the U.S., Europe, Japan, China and other key markets.
Average Trading Volume: 596,623
Technical Sentiment Signal: Sell
Current Market Cap: $1.5B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.